The American College of Rheumatology (ACR) has voiced its approval of CMS’ attempts to lower the cost of drugs under Medicare Part D, but also called on the organization to allow more rheumatologists, including those in small practices, to take part in alternative payment models (APMs).
The American College of Rheumatology (ACR) has voiced its approval of CMS’ attempts to lower the cost of drugs under Medicare Part D, but also called on the organization to allow more rheumatologists, including those in small practices, to take part in alternative payment models (APMs).
Proposed Changes to Medicare Part D
In a November 20 statement, ACR praised the feature of CMS’ proposed rule that would revise the definition of generic drugs to include biosimilars, which CMS refers to as “follow-on biological products,” solely for the purposes of cost-sharing. “Lower-cost alternatives can improve enrollee incentives to choose follow-on biological products over more expensive reference biological products, and can reduce costs to both Part D and Medicare Advantage,” said ACR.
The organization also praised proposed measures to reduce the price of drugs by requiring pharmacy benefit managers (PBMs) to provide a percentage of manufacturers’ rebates negotiated for a drug covered under Part D in the product’s point-of-sale price. “We applaud CMS for exploring mechanisms to lower drug costs through greater pricing transparency on the part of [PBMs],” said ACR. “We are also encouraged that CMS is taking steps to update guidance regarding discriminatory cost-sharing practices.”
However, ACR raised concerns over CMS’ proposal to allow for mid-year formulary changes for generic drugs, saying that patients must have ample time to prepare for any medication switches that may be necessitated by those changes. The proposed rule would permit Part D sponsors to remove brand-named drugs from formularies and replace them immediately with therapeutically equivalent generics upon FDA approval. (Under the proposed rule, all biosimilars would be treated as brand-name drugs and not as generics for the purposes of transitions or mid-year formulary changes, as no biosimilars have been deemed interchangeable by the FDA.) ACR said, “We believe enrollees should have ample notification on any medication switches.”
Alternative Payment Models
ACR is also asking CMS to institute changes that will better allow providers in small practices to participate in alternative payment models (APMs). APMs allow rheumatology practices to comply with the Medicare Access and CHIP Reauthorization Act of 2015 without being subject to the merit-based incentive payment system. However, according to ACR, the financial risk and patient thresholds associated with APMs are too high to allow many practices to participate.
In comment letter to CMS, ACR’s president, David I. Daikh, MD, PhD, said, “We strongly suggest to CMS a proposal to lower the threshold for requirements to make 'qualifying participant' in an advanced APMs more achievable for smaller practices. We propose CMS lower the patient count threshold from 20% to 10%, lower the payment threshold from 25% to 15%, and consider delaying or softening the planned year-over-year increases in these thresholds.”
ACR is currently developing its own APM, which it unveiled this month at the organization’s annual meeting in San Diego, California, specific to the treatment of rheumatoid arthritis.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.